M
Michael J. Keating
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1192
Citations - 81837
Michael J. Keating is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Chronic lymphocytic leukemia & Leukemia. The author has an hindex of 140, co-authored 1169 publications receiving 76353 citations. Previous affiliations of Michael J. Keating include University of Arkansas for Medical Sciences & Economic and Social Research Council.
Papers
More filters
Journal ArticleDOI
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia
George A. Calin,Calin Dan Dumitru,Masayoshi Shimizu,Roberta Bichi,Simona Zupo,Evan Noch,Hansjuerg Aldler,Sashi Rattan,Michael J. Keating,Kanti R. Rai,Laura Z. Rassenti,Thomas J. Kipps,Massimo Negrini,Florencia Bullrich,Carlo M. Croce +14 more
TL;DR: Detailed deletion and expression analysis shows that miR15 and miR16 are located within a 30-kb region of loss in CLL, and that both genes are deleted or down-regulated in the majority (≈68%) of CLL cases.
Journal ArticleDOI
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
Sergio Giralt,Elihu H. Estey,Maher Albitar,Koen van Besien,Gabriela Rondon,Paolo Anderlini,Susan O'Brien,Issa F. Khouri,James Gajewski,Rakesh Mehra,David F. Claxton,Borje S. Andersson,Miloslav Beran,Donna Przepiorka,Charles Koller,Steve Kornblau,Martin Korbling,Michael J. Keating,Hagop M. Kantarjian,Richard E. Champlin +19 more
TL;DR: It is concluded that purine analog-containing nonmyeloablative regimens allow engraftment of HLA-compatible hematopoietic progenitor cells and warrants further study in patients with leukemia who are ineligible for conventional transplantation with myeloablatives either because of age or concurrent medical conditions.
Journal ArticleDOI
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu,David Marin,Pinaki P. Banerjee,Homer A. Macapinlac,Philip A. Thompson,Rafet Basar,Lucila Nassif Kerbauy,Bethany J Overman,Peter F. Thall,Mecit Kaplan,Vandana Nandivada,Indresh Kaur,Ana Karen Nunez Cortes,Kai Cao,May Daher,Chitra Hosing,Evan N. Cohen,Partow Kebriaei,Rohtesh S. Mehta,Sattva S. Neelapu,Yago Nieto,Michael Wang,William G. Wierda,Michael J. Keating,Richard E. Champlin,Elizabeth J. Shpall,Katayoun Rezvani +26 more
TL;DR: Among 11 patients with relapsed or refractory CD19-positive cancers, a majority had a response to treatment with CAR-NK cells without the development of major toxic effects.
Journal ArticleDOI
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.
Michael J. Keating,Ian W. Flinn,Vinay K. Jain,Jacques-Louis Binet,Peter Hillmen,John C. Byrd,Maher Albitar,Lee R. Brettman,Pedro Santabarbara,Bret Wacker,Kanti R. Rai +10 more
TL;DR: Alemtuzumab induced significant responses in patients with relapsed or refractory B-cell chronic lymphocytic leukemia with clinical benefit in the majority and with acceptable toxicity in a high-risk group.
Journal ArticleDOI
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
Issa F. Khouri,Michael J. Keating,M. Korbling,Donna Przepiorka,Paolo Anderlini,Susan O'Brien,Sergio Giralt,Cindy Ippoliti,B. Von Wolff,James Gajewski,M. Donato,David F. Claxton,Naoto T. Ueno,Borje S. Andersson,Adrian P. Gee,Richard E. Champlin +15 more
TL;DR: The ability to induce remissions with donor lymphocyte infusion in patients with CLL, Richter's, and low-grade and intermediate-grade lymphoma is direct evidence of GVL activity against lymphoid malignancies.